HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma: It is a histone deacetylase (HDAC) inhibitor approved for the treatment of cutaneous T-cell lymphoma and has been used to treat metastatic tumours in several cancer types and is the focus of many clinical trials, including for breast cancer treatment [60–63].